This is an open-label, multicenter study designed to assess the safety, tolerability,
preliminary efficacy and pharmacokinetics of Metatinib Tromethamine tablet in patients with
advanced or metastatic gastric cancer, liver cancer, colorectal cancer,or con squamous NSCLC.
Patients receive Metatinib orally 200mg once daily (QD) or 100mg twice daily (BID) until
disease progression or unacceptable toxicity occurred. The study will determine whether MET
gene mutation, amplification, as well as MET protein overexpression in tumor tissue correlate
with treatment efficacy and clinical outcome. The potential PD biomarker for Metatinib will
also be explored.